AbbVie Inc. (ABBV): Price and Financial Metrics
AbbVie Inc. (ABBV)
Today's Latest Price: $100.48 USD
Updated Jul 15 6:40pm
Add ABBV to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 213 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ABBV Stock Summary
- ABBV has a market capitalization of $148,383,057,763 -- more than approximately 98.92% of US stocks.
- The capital turnover (annual revenue relative to shareholder's equity) for ABBV is -4.59 -- better than only 3.21% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -9.17 for AbbVie Inc; that's greater than it is for just 2.2% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to AbbVie Inc are AMGN, AZN, NVO, BMY, and LLY.
- Visit ABBV's SEC page to see the company's official filings. To visit the company's web site, go to www.abbvie.com.
ABBV Stock Price Chart Technical Analysis Charts
ABBV Price/Volume Stats
| Current price | $100.48 | 52-week high | $100.69 |
| Prev. close | $98.87 | 52-week low | $62.55 |
| Day low | $98.82 | Volume | 5,661,600 |
| Day high | $100.48 | Avg. volume | 11,071,702 |
| 50-day MA | $93.68 | Dividend yield | 4.7% |
| 200-day MA | $86.02 | Market Cap | 148.38B |
AbbVie Inc. (ABBV) Company Bio
Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.
ABBV Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $100.48 | $255.46 | 154% |
Below please find a table outlining a discounted cash flow forecast for ABBV, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that AbbVie Inc ranked in the 67th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 155.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of AbbVie Inc, consider:
- The company's balance sheet shows it gets 69% of its capital from equity, and 31% of its capital from debt. Its equity weight surpasses that of merely 23.64% of free cash flow generating stocks in the Healthcare sector.
- AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than just 11.31% of tickers in our DCF set.
- ABBV's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than just 11.31% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 149% |
| 1% | 152% |
| 2% | 154% |
| 3% | 157% |
| 4% | 159% |
| 5% | 162% |
Want more companies with a valuation profile/forecast similar to that of AbbVie Inc? See MCK, NVO, CHE, PCRX, and DVA.
Loading social stream, please wait...